

# NTCIR RealMedNLP

## Real document-based Medical Natural Language Processing ("Real-MedNLP")



**Eiji Aramaki (\*)**

Nara Institute of Science and Technology, Japan

Design  
Overview



**Shoko Wakamiya**

Nara Institute of Science and Technology, Japan

Baseline  
Evaluation



**Shuntaro Yada**

Nara Institute of Science and Technology, Japan

Task 2  
Case-report task




**Yuta Nakamura**

The University of Tokyo, Japan

Task 1  
Radiography-report task



# Medical NLP History




**We aim to develop a REAL clinical text benchmark**

# Much Variety of Writing style

Doctor C's report

:

10-15 doctors



## Doctor A's report

両肺には軽度の気腫性変化、左肺上葉外側にbullaを認めます。

左肺下葉には内部に空洞を伴う長径7.8cm 大の不整形腫瘍を認め、

同一肺葉内には副結節を疑う複数の病変を認めます(cT4)。

腫瘍は胸膜と広範に接しており、胸膜外脂肪層も一部途絶が見られ、壁側胸膜浸潤を疑います。

肋骨への浸潤ははっきりしません。  
腫瘍は横隔膜とも一部接していますが、浸潤所見ははっきりしません。

左肺門や気管分岐下や大動脈下などの同側の縦隔リンパ節の腫大を認め、転移を疑います(cN2)。

肝嚢胞、軽度脾腫を認めます。

その他、撮像内の腹部に特記所見ありません。

## Doctor B's report

左肺下葉に長径78mm大の腫瘍があり、既知の肺癌と考えます。

左肺下葉中枢側にはsatellite lesionと思われる結節を複数認めます。

胸壁に広く接しており、胸壁脂肪織の消失も認められ、胸壁に浸潤している可能性もあります。

左肺門部、気管分岐下、左下部気管傍リンパ節が腫大しており、リンパ節転移と考えます。

撮像内で肝、骨には転移を認めません。副腎は撮像範囲外です。

# Corpora & Tasks

Name			Language	Task
JMedSTD-RR	<b>NTCIR16</b>	Radiography Report 読影所見	JA, EN, (ZH)	<b>NER</b>
JMedSTD-CR	<b>NTCIR16</b>	Case Report 症例報告	JA, EN, (ZH)	<b>NER+ADE</b>
JMedSTD-TW	<b>NTCIR17</b>	Tweets	JA	<b>NER+ADE</b>
JMedSTD-QA	<b>NTCIR17</b>	QA sites知恵袋	TBD	<b>NER+ADE</b>

All corpora share the same NER label-set



If you build **one** system, you can run **four** tasks

- **NER** (disease name, drug name, datetime, etc.. 10 categories)
- **ADE**
  - What is ADE?
    - **Adverse Drug Event** (shortly **ADE**) is sometimes called **Adverse Drug Reaction (ADR)**, **Signal Detection**, **Side effect detection**. Among various task names, the ADE is popular.
  - The ADE is a task to detect adverse effects caused by a drug.
  - There is no solid formalization ☹



We proposed a new ADE formalization

# ADE in NTCIR = Information Extraction (IE)

ID	SEX	AGE	CATEGORY	DATE
JP0113-2	-1	-1	拡張型心筋症	-1

行 日本語

英語

1 **[D(+)]**拡張型心筋症の**[時(AGE)]**80歳の男性(52kg)で、**[D(+)]**心室頻拍により意識消失となり、**[Mk(+)]**リドカイン**[Mv]**120mg/hを併用した時、**[D(+)]**全身硬直、不随運動が**[C]**出現した(**[Tk]**リドカイン血中濃度は**[Tv]**6.84μg/mL)。

In a **[時(AGE)]**80-year-old male (52 kg) with **[D(+)]**dilated cardiomyopathy, **[D(+)]**ventricular tachycardia resulting in loss of consciousness, when **[Mk(+)]**lidocaine **[Mv]**120 mg/h was used concomitantly, **[D(+)]**general rigidity and involuntary movements **[C]**appeared (**[Tk]**Lidocaine blood concentration was **[Tv]**6.84 μg/mL).

2 **[時(DATE)]**その後**[Mk(-)]**リドカインは**[C]**休薬、減量し**[Mv]**78mg/hの時、**[Mk(+)]**メキシレチンを**[Mv(-)]**200mg/日から**[Mv(+)]**450mg/日に**[C]**増量した**[時(DATE)]**初日に、**[D(+)]**全身硬直、不随運動が**[C]**出現した(**[Tk]**リドカイン血中濃度は**[Tv]**5.7μg/mL)。

**[時(DATE)]**Then **[Mk(-)]**Lidocaine was **[C]**withdrawn and reduced to **[Mv]**78 mg/h when **[Mk(+)]** Mexiletine was **[C]**increased from **[Mv(-)]**200 mg/day to **[Mv(+)]**450 mg/day on the **[時(DATE)]**first day. **[D(+)]**general stiffness and involuntary movements **[C]**appeared (**[Tk]**Lidocaine blood level was **[Tv]**5.7 μg/mL).

3 更に**[Mk(+)]**リドカイン**[Mv]**18 mg/hで**[時(CC)]**投与中に再び**[D(+)]**副作用が**[C]**出現したため、**[Mk(-)]**リドカインを**[C]**中止したところ**[D(-)]**副作用は認められなくなった。

Furthermore, **[Mk(+)]**lidocaine **[Mv]**18 mg/h during **[時(CC)]**administration again **[D(+)]**side effects **[C]**appeared, **[Mk(-)]**Lidocaine was **[C]**discontinued, and **[D(-)]**side effects were no longer observed.

Disease Name	ADE or not
General stiffness and involuntary movement	ADE Positive
Side Effects	ADE Suspicious
Dilated cardiomyopathy	ADE-Negative
Drug Name	ADE Trigger or not
Lidocaine	ADE trigger Positive
Mexiletine	ADE trigger Suspicious

A system fills the slots

# Schedule for Workshop

- Sep 2021: Data-set Release\*
- Sep-Nov 2021: Dry Run\*
- Dec 2021-Feb 2022: Formal Run\*
- Feb 1, 2022: Evaluation Result Release
- Feb 1, 2022: Draft Task Overview Paper Release
- Mar 1, 2022: Draft Participant Paper Submission Due
- May 1, 2022: All Camera-ready Paper Submission Due

\* modified

# Collaboration

With JST-project (医薬品安全性監視のための言語を超えた知識強化情報抽出)

- AIP-Japan, German, France

- Möller, Sebastian@DFKI



- Zweigenbaum, Pierre@CNRS



- Matsumoto, Yuji@AIP



- Aizawa, Akiko@NII



# NTCIR RealMedNLP

Thank you



## Real document-based Medical Natural Language Processing ("Real-MedNLP")



**Eiji Aramaki (\*)**

Nara Institute of Science and Technology, Japan



**Shoko Wakamiya**

Nara Institute of Science and Technology, Japan



**Shuntaro Yada**

Nara Institute of Science and Technology, Japan



**Yuta Nakamura**

The University of Tokyo, Japan